Last reviewed · How we verify

NCT05413629: education

The Effect of Web Based Education on the Level of Coping With Infertility Stress and Infertility Self-Efficacy

Completed NA Last updated 23 February 2024
What this trial tests

NA trial testing Web-based patient education for the intrauterine insemination (IUI) treatment process in Infertility, Female in 132 participants. Completed in 30 December 2022.

Timeline
1 April 2022
Primary endpoint
30 December 2022
30 December 2022

Quick facts

Lead sponsorDuzce University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposesupportive care
Enrollment132
Start date1 April 2022
Primary completion30 December 2022
Estimated completion30 December 2022
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Duzce University

Who can join

Adults 23 to 39, female only, with Infertility, Female or Educational Problems. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In the study, it is aimed to reduce the infertility stress level of women undergoing infertility treatment, to increase the level of coping with infertility stress, to increase infertility self-efficacy, to evaluate the usability of web-based education in the field of infertility, to increase the effectiveness and quality of education by integrating web-based education into the nursing care process, and continuous traceability, to prevention of possible wrong treatment process management in the field of infertility, to prevention of possible loss of cycles and to prevention the material and moral couple from being adversely affected by this process. Method: The study was planned to be carried out between 20.01.2022 and 01.06.2023 with women between the ages of 23-39 who applied to Düzce University Health Practice and Research Center, Infertility Polyclinic. In the research, the Solomon four-group design sample design consisting of two experimental and two control groups will be used. The study planned to consist of a total of 132 patients, 33 patients in each group, taking into account possible data losses. By design, all of the pre-test and post-test measurement tools will be applied to the first experimental and control group, and only the post-test measurement tools will be applied to the second experimental and control group. Randomization will be applied in determining the experimental and control groups. The data will be collected using Personal Information Form (Appendix-1), Infertility Stress Scale (ISS) (Appendix 2), Coping with the Infertility Stress Scale (CISS) (Appendix-3), and Infertility Self-Efficacy Scale - Short Form (ISE-SF) (Appendix 4). Research data will be collected in approximately day 24 to 27 days for each patient from the initiation of Controlled Ovarian Stimulation (COS) treatment to pregnancy determination of patients planned for intrauterine insemination (IUI) treatment. Web-based training is 60 minutes in total, including 4 modules. The web-based training content includes general information about fertility, infertility diagnosis-treatment methods, drugs used in IUI treatment and its application, and issues to be considered after IUI.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. The effect of bladder training with mobile application on quality of life and sexual satisfaction in women with overactive bladder: randomized controlled study.
    Yalazı RÖ, Demirci N. · · 2025 · PMID 40996496 · DOI 10.1007/s00345-025-05917-6

Verify or expand the search:

Other recruiting trials for Infertility, Female

Currently open trials in the same condition.

Other Duzce University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05413629.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing